Updates On Drug Discovery In Ovarian Cancer

by / 3 Comments / 8 View / September 30, 2014

Updates on drug discovery in ovarian cancer

Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agents include compounds that disrupt angiogenesis through a variety of mechanisms. Other oncogenic pathways are also specifically targeted such as PARP, MEK, and topoisomerase inhibitors which are currently being studied in phase III trials. Various cytotoxic agents, as well as therapeutic vaccines, are also under investigation, and continue to demonstrate
promising new data. The relevant agents in the treatment of ovarian cancer which have demonstrated positive phase II activity will be discussed.
For the full version of the article click here:

Updates on drug discovery in ovarian cancer

3 Comment

  1. Thanks for your marvelous posting! I genuinely enjoyed reading it, you will be a great author. I will be sure to bookmark your blog and will eventually come back from now on. I want to encourage one to continue your great work, have a nice weekend!

  2. My family all the time say that I am wasting my time here at web, however I know I am getting knowledge every day by reading thes nice articles or reviews.

  3. An intriguing discussion is definitely worth comment. I think that you should write more about this subject, it may not be a taboo matter but usually people do not speak about such topics. To the next! Kind regards!!

Your Commment

Email (will not be published)